^EINDHOVEN, Netherlands, LAUSANNE, Switzerland and BOSTON, MA, March 15, 2024 (GLOBE NEW updated:
The guide to your wealth!
Request for free here… NEWSWIRE) — The medical technology company ONWARD Medical NV (Euronext: ONWD),
the innovative therapies to restore movement, independence and
Health for people with spinal cord injuries (SCI)
developed, announced today the appointment of two key members of its
Leadership teams known to clinical research and commercial
to advance the company’s activities. Both new additions will be in the USA
and report to Dave Marver, CEO.
Neue VP Global Clinical & Regulatory – Erika Ross, PhD
Dr. Erika Ross will join ONWARD as Vice President, effective January 23, 2023,
Global Clinical & Regulatory. In this newly created position
She will lead global clinical and regulatory activities
from ONWARD.
Before working at ONWARD, Dr. Erika Ross as Director, Global Clinical
& Applied Research at Abbott Neuromodulation. She previously headed as
Neuroscience Director at Cala Health the scientific research program,
that for the De Novo approval and introduction of the neurostimulation technology of the
company led. Miss Dr. Ross was also at the Mayo Clinic as
Deputy Director of the Medical Device Innovation Accelerator
Department of Surgery and as an assistant professor in the Department of
neurological surgery. She holds a B.Sc. in
Biology and Economics as well as an M.Sc. in molecular biology from the
University of Denver and received his doctorate in neuroscience from the Mayo Clinic.
“I’m pleased, Dr. Welcoming Erika Ross to our leadership team,”
said Dave Marver, Chief Executive Officer. ?Your comprehensive expertise in
The field of neuromodulation will help our company prepare for the
Commercialization of the numerous promising therapies in our pipeline
strengthen. Erika also brings excellent relationships with researchers and
Clinicians with whom they met during their work in neuroscience and the
Neurosurgery at the Mayo Clinic and after moving to the
industry has maintained.”
“I feel honored to be involved in the further development of ONWARD’s therapies
to be able to help meet the great unmet needs of people
to cover spinal cord injuries. Also I am very happy to be part of this
committed and extremely capable leadership teams committed to this
is committed to making these important therapies accessible as quickly as possible
do,” commented Dr. Erika Ross.
Neue VP, Global Marketing – Sarah Moore
Sarah Moore will become Vice President, Global, effective February 1, 2023
Marketing by ONWARD. In this role she will be responsible for the worldwide
ONWARD’s marketing activities, including:
Product management and market launch planning.
Sarah Moore previously worked as Head of Commercial Marketing at Nevro, a
Implantable neuromodulation company. Before that she had different ones
Leading positions in global marketing for several medical technology companies
at Johnson & Johnson, most recently as head of Advanced Imaging
business unit of J&J. Ms. Moore holds an MBA from the
Duke University and a BA in German from Washington and Lee University.
?Sarah Moore’s extensive experience in medical device marketing
and especially neuromodulation therapies will be invaluable to us
be as we prepare to receive our first therapy later this year
“It’s coming to market this year,” said Dave Marver. “It brings a variety of
Skills that go far beyond marketing and help us
Scaling will help.”
“I am fascinated by ONWARD’s mission and it is an honor to do so
to complement a first-class team dedicated to restoring
physical functions in people with spinal cord injuries.
I look forward to working with the medical community to address this
bringing groundbreaking therapy to market,” added Sarah Moore.
About ONWARD Medical
ONWARD is a medical technology company that provides innovative therapies
Restoring movement, independence and health in people with
Spinal cord injuries developed. ONWARD’s work is based on more than
a decade of basic research and preclinical development in
carried out in the world’s leading neuroscience laboratories. The ARC
Therapy of ONWARD using implantable (ARC-IM) or external (ARC-EX)
Systems can be carried out, serves the targeted, programmed
Stimulation of the spinal cord to enable movement and other functions in humans
with spinal cord injuries and thus improve their quality of life
improve.
ONWARD has five breakthrough device designations from the US FDA
that include both ARC-IM and ARC-EX. ARC-EX is an external,
non-invasive platform consisting of a wearable stimulator and a
wireless programming device. Positive topline results were reported in 2022
the company’s first pivotal study, Up-LIFT, was published in the
the ability of ARC-EX therapy to improve the strength and function of the
upper extremities was evaluated. The company is now preparing
Applications for approval for the USA and Europe. ARC-IM consists of one
implantable pulse generator and an electrode placed near the
Spinal cord is placed. The company has the 2022 ARC-IM neurostimulator
first used in humans.
ONWARD’s headquarters are located in Eindhoven, Netherlands. The
The company has a science and technology center in Lausanne,
Switzerland, and a growing presence in the US in Boston, Massachusetts. ONWARD
connects an academic partnership with .NeuroRestore, a collaboration
between the Swiss Federal Institute of Technology in Lausanne (EPFL) and the
Lausanne University Hospital (CHUV). More information about the company
can be found at ONWD.com (The 2023 financial calendar
can be found at IR.ONWD.com (https://ir.onwd.com/).
For corporate inquiries:
info@onwd.com (mailto:info@onwd.com)
For media inquiries:
MC Services AG
USA: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0
media@onwd.com (mailto:media@onwd.com)
For investor inquiries:
investors@onwd.com (mailto:investors@onwd.com)
Disclaimer
Certain statements, beliefs and opinions contained in this press release are
future-oriented and reflect the current expectations and forecasts
company or the board of directors of the company with regard to future
events reflected. It is in the nature of things that future-oriented
Statements involve a number of risks, uncertainties and assumptions
could cause actual results or events to differ materially
differ from those expressed or expressed in the forward-looking statements
be implied. These risks, uncertainties and assumptions could
Outcome and financial impact of the plans described herein and
negatively influence events. A variety of factors including,
but not limited to, changes in demand, competition and
Technology, can cause actual events, achievements
or results deviate significantly from the expected development.
Forward-looking statements in this press release relate to past
Any reference to trends or activities should not be understood as a guarantee that
these trends or activities will continue in the future. Therefore rejects this
Company expressly disclaims any obligation to provide updates or
Corrections to the forward-looking statements contained in this press release
to publish statements if the expectations or the events,
Conditions, assumptions or circumstances on which these forward-looking
Based on statements, change. Neither the company nor its advisors or
representatives, nor one of its subsidiaries, nor the executive officers
or employees of such persons guarantee that the assumptions made by such persons
the forward-looking statements are based on, are error-free
you assume responsibility for the future accuracy of this
any forward-looking statements or actual statements contained in this press release
Occurrence of the forecast developments. You shouldn’t be in
Inappropriately rely on forward-looking statements, which are intended only for the purpose
as of the date of this press release.
°
Source: dpa-AFX
2024-03-15 23:18:35
#GNWAdhoc #ONWARD #strengthens #management #team #key #positions #areas #Clinical #Regulatory #Marketing #boerse.de
